Technology Appraisal Virtual Committee Meeting [Committee D]

**Minutes: Confirmed**

**Date and time: Wednesday 8 July 2020 at 9:30am [Held via Zoom**]

## Committee Members Present:

* Chair Stephen O’Brien Present for all notes
* Nabeel Alsindi Present for all notes
* Matt Bradley Present for all notes
* Sofia Dias Present for all notes
* Professor Rachel Elliott Present for all notes
* Professor Paula Ghaneh Present for all notes
* Natalie Hallas Present for all notes
* Rebecca Harmston Present for all notes
* Dr Andrew Hitchings Present for all notes
* Robert Hodgson Present for all notes
* Dr Bernard Khoo Present for all notes
* Nigel Langford Present for all notes
* Dr Soo Fon Lim Present for all notes
* Dr Guy Makin Present for all notes
* Professor Gary McVeigh Present for all notes
* Professor David Meads Present for all notes
* Giles Monnickendam Present for all notes
* Ugochi Nwulu Present for all notes
* Dr Malcolm Oswald Present for all notes
* Baljit Singh Present for all notes
* Dr Lindsay Smith Present for all notes

## NICE Staff Present:

* Jasdeep Hayre, Associate Director, Present for all notes
* Louise Jafferally, Project Manager, Present for all notes
* Abi Senthinathan, Technical Analyst, Present for all notes
* Alex Filby, Technical Adviser, NICE, Present for all notes
* Mandy Brereton, Assistant Project Manager, Present for all notes
* Gemma Smith, Coordinator, Present for all notes
* Mandy Tonkinson, Public Involvement Adviser, Present for notes 1 to 2.4
* Sandra Robinson, Coordinator, Present for notes 1 to 2.4

## Evidence Review Group:

* Robert Wolff, Kleijnen Systematic Reviews, Present for notes 1 to 2.4
* Ben Wijnen, Kleijnen Systematic Reviews, Present for notes 1 to 2.4
* Sabine Grimm, Kleijnen Systematic Reviews, Present for notes 1 to 2.4

## Clinical and Patient Experts:

* Steve Williamson, NHS England Commissioning Expert, Present for all notes
* Julia Scarisbrick, Clinical Expert, Consultant Dermatologist & Lead Cutaneous Lymphoma Service, Present for notes 1 to 2.4
* Eve Gallop-Evans, Clinical Expert, Consultant Clinical Oncologist & Clinical Director, Present for notes 1 to 2.4
* Stan Cummins, Patient Expert, Present for notes 1 to 2.4
* Stephen Scowcroft, Patient Expert, Director of Operations and External Affairs, Lymphoma Action, Present for notes 1 to 2.4
* George Fletcher, Patient Expert, Present for notes 1 to 2.4

## Other non-public attendees:

* Ann Greenwood, Medical Editor, NICE, Present for all notes
* Maroulla Whiteley, Business Analyst, NICE, Present for all notes
* Zain Hussain, Technical Analyst, NICE, Present for all notes
* George Braileanu, Technical Analyst, NICE, Present for all notes
* Ross Wilkinson, Technical Analyst, NICE, Present for all notes
* Fatima Chunara, Technical Analyst, NICE, Present for all notes
* Victoria Kelly, Technical Advisor, NICE, Present for all notes
* Jamie Jason, Co-ordinator, NICE, Present for all notes
* Anna Wasielewska, Technical Analyst, NICE, Present for all notes
* Melanie Carr, Technical Analyst, NICE, Present for all notes
* Rachel Neary-Jones, Programme Manager, NICE, Present for all notes
* Julie Kennedy, Senior Technical Analyst, NICE, Present for all notes
* Claire Hawksworth, Technical Analyst, NICE, Present for all notes
* Thomas Strong, Technical Adviser, NICE, Present for all notes
* Frances Pang, HST Committee Member, Present for all notes
* Willem Wiltox, Kleijnen Systematic Reviews, Present for notes 1 to 2.4

Notes

## Appraisal of Mogamulizumab for previously treated mycosis fungoides and Sézary syndrome [ID1405]

### Part 1 – Open session

1. The Chair welcomed the invited clinical and patient experts, Evidence Review Group [ERG] representatives and representatives from Kyowa Kirin.
2. The Chair asked all committee members, experts, ERG representatives and NICE staff present to declare any relevant interests

	* 1. Professor David Meads declared a non-financial professional & personal interest as the University of Leeds has received funding from Sanofi for research in an unrelated area.
		2. It was agreed that this declaration would notprevent David from participating in this section of the meeting.
		3. Amanda Matse-Orere declared a financial interest as she works for a competitor manufacturer.
		4. It was agreed that this declaration wouldprevent Amanda from participating on this topic.
		5. Julia Scarisbrick declared the following financial interests as she was PI on Mavoric Trial 2, received consultancy fee from Kyowa Kirin and received a research grant whilst studying quality of life 2019 at University Hospital Birmingham.
		6. It was agreed that this declaration would not prevent Julia from participating on this topic.
	1. No further conflicts of interest were declared for this appraisal.
	2. The Chair introduced the lead team who gave presentations on the clinical effectiveness and cost effectiveness of the treatment.
	3. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

### Part 2 – Closed session [company representatives, clinical and patient experts, ERG/AG representatives and members of the public were asked to leave the meeting]

1. Agreement on the content of the Appraisal Consultation Document [ACD] was discussed by the committee.
2. The committee decision was based on consensus.

1. The committee asked the NICE technical team to prepare the Appraisal Consultation Document [ACD] in line with their decisions.